FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug
source: pixabay.com

FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug

According to a story from globenewswire.com, the US Food and Drug Administration (FDA) recently accepted the New Drug Application (NDA) for arimoclomol. This application is for the use of the…

Continue Reading FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug
September is Charcot-Marie-Tooth Disease Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

September is Charcot-Marie-Tooth Disease Awareness Month: Spreading Rare Disease Awareness

September is recognized as Charcot-Marie-Tooth disease (CMT) Awareness Month. Although this illness is one of the most widespread inherited genetic disorders, there is still a significant need to spread awareness…

Continue Reading September is Charcot-Marie-Tooth Disease Awareness Month: Spreading Rare Disease Awareness
Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation
source: pixabay.com

Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation

According to a story from BioSpace, Ziopharma Oncology, Inc. has recently announced that its investigational therapy Ad-RTS-hIL-12 with veledimex (also called Controlled IL-12) has been given Rare Pediatric Disease designation…

Continue Reading Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation
Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
source: pixabay.com

Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

According to a story from BioSpace, the biopharmaceutical company Clene Nanomedicine, Inc., has recently announced that it has completed the process of enrollment patient participants in its upcoming phase 2…

Continue Reading Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial
source: pixabay.com

Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial

According to a story from BioSpace, the biopharmaceutical company Zogenix, Inc., has recently announced the release of results from a phase 3 clinical trial testing the company's drug fenfluramine (marketed…

Continue Reading Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial

New 5-Year Survival Data Available on Maralixibat for PFIC2

This year, the Digital International Liver Congress took place online from August 27-29, thanks to COVID-19. During the conference, biopharmaceutical company Mirum Pharmaceuticals announced data from its Phase 2 INDIGO…

Continue Reading New 5-Year Survival Data Available on Maralixibat for PFIC2
September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness

According to a story from Newswise, September is recognized as Pulmonary Fibrosis Awareness Month. This includes idiopathic pulmonary fibrosis (IPF), or disease without an identifiable cause. In the midst of…

Continue Reading September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness
Study Shows How Extra PMP22 Gene in Patients with CMT1A May Cause Cellular Toxicity
qimono / Pixabay

Study Shows How Extra PMP22 Gene in Patients with CMT1A May Cause Cellular Toxicity

According to Charcot-Marie-Tooth News, patients with Charcot-Marie-Tooth disease type 1A (CMT1A) have an extra PMP22 gene. However, new research shows that this excess gene causes a toxic accumulation of protein within cells.…

Continue Reading Study Shows How Extra PMP22 Gene in Patients with CMT1A May Cause Cellular Toxicity